- Home
- PTCT vs CGON Comparison
PTCT vs CGON Comparison
Compare PTCT & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTCT
- CGON
- Stock Information
- Founded
- PTCT 1998
- CGON 2010
- Country
- PTCT United States
- CGON United States
- Employees
- PTCT N/A
- CGON N/A
- Industry
- PTCT Biotechnology: Pharmaceutical Preparations
- CGON
- Sector
- PTCT Health Care
- CGON
- Exchange
- PTCT Nasdaq
- CGON NYSE
- Market Cap
- PTCT N/A
- CGON 2.3B
- IPO Year
- PTCT 2013
- CGON 2024
- Fundamental
- Price
- PTCT $41.81
- CGON $27.97
- Analyst Decision
- PTCT Hold
- CGON Strong Buy
- Analyst Count
- PTCT 13
- CGON 10
- Target Price
- PTCT $51.85
- CGON $65.11
- AVG Volume (30 Days)
- PTCT 530.0K
- CGON 987.7K
- Earning Date
- PTCT 02-27-2025
- CGON 02-02-2025
- Dividend Yield
- PTCT N/A
- CGON N/A
- EPS Growth
- PTCT N/A
- CGON N/A
- EPS
- PTCT N/A
- CGON N/A
- Revenue
- PTCT $900,664,000.00
- CGON $684,000.00
- Revenue This Year
- PTCT N/A
- CGON $210.00
- Revenue Next Year
- PTCT $14.26
- CGON N/A
- P/E Ratio
- PTCT N/A
- CGON N/A
- Revenue Growth
- PTCT 12.84
- CGON 258.12
- 52 Week Low
- PTCT $23.58
- CGON $25.77
- 52 Week High
- PTCT $54.16
- CGON $50.23
- Technical
- Relative Strength Index (RSI)
- PTCT 37.13
- CGON 38.91
- Support Level
- PTCT $43.50
- CGON $27.84
- Resistance Level
- PTCT $45.59
- CGON $32.11
- Average True Range (ATR)
- PTCT 1.74
- CGON 1.41
- MACD
- PTCT -0.49
- CGON 0.16
- Stochastic Oscillator
- PTCT 2.69
- CGON 7.59
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.